GO:0022832 voltage-gated channel activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0022832 (voltage-gated channel activity) is a molecular function describing transmembrane solute transfer through a channel whose open state depends on the membrane voltage in which it is embedded.
• Voltage-gated sodium, potassium, and calcium channels are the principal protein families that execute this function, and their gating underlies electrical signaling in excitable cells.
• Pharmacological modulation of these channels is clinically validated: local anesthetics block voltage-gated sodium channels, while Kv7 potassium channel openers are pursued for epilepsy.
• Voltage-gated ion channel gene expression is developmentally and tissue-specifically regulated, as shown in embryonic and adult chicken myocardium.
• Disease-causing mutations in voltage-gated channel genes can be functionally rescued by small lipophilic compounds, demonstrating druggability of gating defects.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models are essential to establish causal links between channel genes and physiology or disease.
Description
GO:0022832, voltage-gated channel activity, is a molecular function ontology term that captures the ability of a membrane protein to transfer a solute across a lipid bilayer through a channel whose open state is controlled by the voltage across that membrane. This activity is the biophysical foundation of electrical excitability: it converts changes in membrane potential into ion flux, and thereby into signals that propagate along nerves, contract muscle, and shape cardiac rhythm. Because the channel open state is voltage-dependent, these proteins behave as molecular sensors and effectors simultaneously, coupling membrane potential to ion permeation. For researchers, GO:0022832 is a precise annotation that distinguishes voltage-gated channels from ligand-gated, mechanically gated, or constitutively open channels. The term is used in functional genomics, electrophysiology, and pharmacology to classify genes such as SCN, KCNQ, and CACNA family members that share this gating mechanism. Its importance extends from basic biophysics to translational medicine, since voltage-gated sodium channel activators and blockers are widely studied for pain and anesthesia, and Kv7 potassium channels are actively targeted for epilepsy. This article synthesizes the QuickGO definition of GO:0022832 with verified PubMed literature to describe the mechanism, the genes that carry this activity, disease relevance, and the experimental models, including CRISPR-based approaches, that are used to study it.
voltage-gated channel activity At A Glance
| GO ID | GO:0022832 |
|---|---|
| GO term | voltage-gated channel activity |
| Ontology | molecular_function |
| Synonym | none listed in QuickGO |
| Definition | Enables the transmembrane transfer of a solute by a channel whose open state is dependent on the voltage across the membrane in which it is embedded. |
| Major function | Voltage-dependent transmembrane solute flux underlying electrical signaling |
| Representative families | Voltage-gated sodium, potassium, and calcium channels |
| Pharmacological relevance | Targets of local anesthetics and Kv7 openers |
| Disease relevance | Channelopathies including epilepsy and neurodevelopmental disorders |
What Is GO:0022832?
In our own words, GO:0022832 describes a molecular function in which a protein forms a transmembrane channel that allows a solute to cross a membrane, and the probability that this channel is open is governed by the voltage difference across the membrane in which the channel sits. The defining feature is voltage dependence of gating, not the identity of the permeant ion or the direction of transport. This function is therefore assigned to proteins that combine a voltage-sensing module with a pore module, enabling them to open or close in response to changes in membrane potential.
Why Is voltage-gated channel activity Important in Cell Biology?
Voltage-gated channel activity is important because it is the molecular basis of electrical signaling in excitable tissues, and because its dysfunction or pharmacological modulation directly alters nerve conduction, cardiac rhythm, and muscle contraction. The same activity is a validated drug target: local anesthetics act by blocking voltage-gated sodium channels, and Kv7 potassium channels are being targeted for epilepsy therapy. In addition, developmental and tissue-specific expression of voltage-gated ion channel genes shapes the functional maturation of organs such as the heart, and disease-associated mutations in these channels can be rescued by small molecules, underscoring their therapeutic tractability.
• Provides the biophysical basis for action potentials and electrical excitability.
• Enables rapid ion flux that couples membrane potential to cellular responses.
• Is the direct target of clinically used local anesthetics.
• Is a therapeutic focus for epilepsy through Kv7 potassium channel modulation.
• Shows developmentally regulated expression in myocardium.
• Can be impaired by neurodevelopmental-associated mutations that are pharmacologically rescuable.
• Contributes to nociceptive signaling relevant to pain research.
• Is modulated by endogenous and pharmacological activators of sodium channels.
• Is essential for coronary blood flow regulation during exercise through ion channel-dependent vascular control.
• Provides a tractable target for CRISPR-based functional genomics.
What Happens During voltage-gated channel activity?
Voltage sensing and conformational change
In simple terms: The channel detects changes in the electrical charge across the membrane and changes shape in response.
Voltage-gated channels contain a voltage-sensing domain that responds to changes in the transmembrane electric field. In voltage-gated sodium channels, structure-function studies have defined how the channel protein couples voltage sensing to pore opening. This sensing step is the defining event of GO:0022832, because the open state depends on the voltage across the membrane in which the channel is embedded.
Pore opening and ion permeation
In simple terms: Once the channel changes shape, a pore opens and ions flow through.
After voltage sensing, the channel pore opens to allow transmembrane solute transfer. For voltage-gated sodium channels, the permeation pathway and its selectivity have been dissected by structure-function analysis. The resulting ion flux is the functional output of GO:0022832 and underlies electrical signaling in excitable cells.
Inactivation and closure
In simple terms: The channel then closes again, often quickly, so the signal is brief.
Voltage-gated channels typically transition to a non-conducting state after opening. The gating cycle of opening and closing is central to shaping electrical signals, and pharmacological agents such as local anesthetics stabilize non-conducting states of voltage-gated sodium channels. This dynamic control distinguishes voltage-gated channel activity from unregulated pore activity.
Pharmacological modulation of gating
In simple terms: Drugs can change how easily the channel opens or closes.
Voltage-gated channel activity is modulated by small molecules. Voltage-gated sodium channel activators alter gating to increase channel opening, whereas local anesthetics block the channel. Kv7 potassium channel openers are being developed to enhance channel activity for epilepsy, and lipophilic compounds can restore function to neurodevelopmental-associated KCNQ3 mutations.
Key Genes Involved in GO:0022832 voltage-gated channel activity
The genes below encode proteins that carry or directly regulate voltage-gated channel activity, based on the verified literature and standard gene nomenclature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SCN1A | Voltage-gated sodium channel alpha subunit | Epilepsy and neurodevelopmental channelopathy research |
| SCN2A | Voltage-gated sodium channel alpha subunit | Neuronal excitability and sodium channel pharmacology |
| SCN3A | Voltage-gated sodium channel alpha subunit | Brain sodium channel function and gating studies |
| SCN4A | Voltage-gated sodium channel alpha subunit | Muscle excitability and channelopathy models |
| SCN5A | Voltage-gated sodium channel alpha subunit | Cardiac conduction and arrhythmia research |
| SCN9A | Voltage-gated sodium channel alpha subunit | Nociception and pain research |
| SCN10A | Voltage-gated sodium channel alpha subunit | Sensory neuron excitability and pain |
| KCNQ2 | Voltage-gated potassium channel subunit | Epilepsy and Kv7 channel pharmacology |
| KCNQ3 | Voltage-gated potassium channel subunit | Neurodevelopmental disorders and pharmacological rescue |
| KCNQ1 | Voltage-gated potassium channel subunit | Cardiac repolarization and channel studies |
| KCNA1 | Voltage-gated potassium channel subunit | Neuronal excitability and gating research |
| KCNH2 | Voltage-gated potassium channel subunit | Cardiac action potential repolarization |
| CACNA1A | Voltage-gated calcium channel subunit | Neuronal calcium signaling and excitability |
| CACNA1C | Voltage-gated calcium channel subunit | Cardiac and neuronal calcium channel function |
| CACNA1S | Voltage-gated calcium channel subunit | Muscle excitation-contraction coupling |
| SCN1B | Voltage-gated sodium channel auxiliary subunit | Modulation of sodium channel gating |
| KCNE1 | Voltage-gated potassium channel auxiliary subunit | Regulation of Kv channel activity |
How Is voltage-gated channel activity Regulated?
Voltage-gated channel activity is regulated at multiple levels. At the protein level, gating is controlled by the membrane potential itself, and channel opening can be further modulated by pharmacological agents such as local anesthetics that stabilize non-conducting states or activators that promote opening. Auxiliary subunits and accessory proteins can modify channel trafficking and gating, as recognized in structure-function studies of voltage-gated sodium channels. At the transcriptional level, expression of voltage-gated ion channel genes is developmentally and tissue-specifically regulated, as demonstrated in embryonic and adult chicken myocardium. In addition, disease-associated mutations can alter channel function, and small lipophilic compounds can restore function to mutant KCNQ3 channels, indicating that channel activity is a modifiable node.
voltage-gated channel activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| KCNQ3 | Neurodevelopmental disorder with impaired channel function | Point-mutation knock-in to model patient variant and test pharmacological rescue |
| KCNQ2 | Epilepsy and Kv7 channel dysfunction | Knockout or point-mutation model to assess seizure susceptibility |
| SCN1A | Epilepsy and sodium channelopathy | Knockout or knock-in of patient mutation in neuronal cells |
| SCN9A | Pain and nociception | Overexpression or knockout in sensory neuron models |
| SCN5A | Cardiac conduction and arrhythmia | Knock-in of variant in cardiomyocyte model |
Epilepsy and neurodevelopmental channelopathies
Voltage-gated channel activity is directly implicated in epilepsy, where Kv7 potassium channels are a therapeutic target. Mutations in KCNQ3 associated with neurodevelopmental disorders impair channel function, and lipophilic compounds can restore function to these mutant channels. These findings link GO:0022832 to seizure susceptibility and developmental brain disorders.
Pain and nociception
Voltage-gated sodium channels are central to nociceptive signaling, and their activators are studied for their effects on pain pathways. Nociception physiology involves voltage-gated channel activity in sensory neurons. Consequently, genes such as SCN9A and SCN10A are research targets for pain disorders.
Cardiac and vascular biology
Voltage-gated ion channel gene expression in the myocardium changes during development, as shown in embryonic and adult chickens. Coronary blood flow regulation during exercise involves ion channel-dependent vascular control. These observations connect GO:0022832 to cardiac and vascular physiology.
From voltage-gated channel activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is the channel gene required for electrical excitability? | CRISPR knockout in excitable cell line or primary neurons |
| Does a patient variant alter gating? | Point-mutation knock-in of the variant |
| Can a drug rescue mutant channel function? | Knock-in of mutant channel plus pharmacological treatment |
| Where is the channel protein localized? | Tagged knock-in with fluorescent or epitope tag |
| Does overexpression change excitability? | Overexpression of wild-type or mutant channel |
| Which genes modify channel activity? | CRISPR library screening in a channel-dependent assay |
How to Study the voltage-gated channel activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Patch-clamp electrophysiology | Ion currents and gating properties | Assigning voltage-gated channel activity to a gene product |
| Voltage-clamp fluorometry | Conformational changes during gating | Studying voltage-sensing domain movement |
| RNA-seq | Expression levels of channel genes | Developmental and tissue profiling |
| Pharmacological assays | Drug effects on channel opening or block | Testing activators or blockers |
| CRISPR knockout | Loss-of-function phenotype | Determining requirement for channel gene |
| CRISPR point mutation | Effect of specific variant | Modeling channelopathy mutations |
| CRISPR knock-in reporter | Protein localization and expression | Tagging endogenous channel |
| CRISPR overexpression | Gain-of-function phenotype | Testing sufficiency of channel activity |
Electrophysiology
Patch-clamp and voltage-clamp recordings directly measure voltage-gated channel activity by quantifying currents in response to controlled membrane potentials. These methods are the gold standard for assigning GO:0022832 and for testing how mutations or drugs alter gating.
Expression profiling
Transcriptomic profiling of voltage-gated ion channel genes reveals developmental and tissue-specific expression patterns, as shown in embryonic and adult chicken myocardium. Such profiling helps prioritize channel genes for functional study.
Pharmacological profiling
Pharmacological agents that activate or block voltage-gated channels are used to probe channel function. Voltage-gated sodium channel activators and local anesthetics are established tools, while Kv7 openers are studied for epilepsy.
Genetic and CRISPR-based perturbation
CRISPR knockout, point mutation, knock-in, and overexpression allow causal testing of channel genes. For example, knock-in of a KCNQ3 mutation enables assessment of channel dysfunction and pharmacological rescue.
How CRISPR Can Be Used to Study GO:0022832 voltage-gated channel activity
Knockout
CRISPR knockout of a voltage-gated channel gene removes the protein and tests whether the channel is required for a given electrical or physiological response. This approach is foundational for linking genes such as SCN or KCNQ family members to GO:0022832-dependent phenotypes.
Point Mutation
CRISPR point mutation introduces a specific nucleotide change to model disease-associated variants. This is particularly useful for channelopathies, where single amino acid substitutions can alter gating, as illustrated by KCNQ3 mutations that impair function and can be rescued pharmacologically.
Knock-in
CRISPR knock-in can insert a tag, reporter, or entire mutant allele at the endogenous locus. Tagged knock-in allows visualization of channel localization, while mutant knock-in models patient-specific gating defects for drug testing.
Overexpression
CRISPR-mediated overexpression or cDNA-based overexpression increases channel abundance to test sufficiency of voltage-gated channel activity. This can reveal gain-of-function effects relevant to excitability disorders.
How EDITGENE Supports voltage-gated channel activity Research
Researchers studying voltage-gated channel activity-related genes often need to determine whether a candidate gene is causally involved in a physiological or disease phenotype, and CRISPR-based models provide a direct route to that causal test. By combining knockout, point mutation, knock-in, and overexpression with functional assays such as electrophysiology, it becomes possible to link specific channel genes to GO:0022832 and to evaluate therapeutic hypotheses.
Contact EDITGENE today to design your custom CRISPR model for voltage-gated channel activity research.
Frequently Asked Questions About voltage-gated channel activity
What is GO:0022832 voltage-gated channel activity?
GO:0022832 is a molecular function term describing transmembrane solute transfer through a channel whose open state depends on the voltage across the membrane in which it is embedded.
What genes are involved in voltage-gated channel activity?
Genes encoding voltage-gated sodium, potassium, and calcium channels, such as SCN1A, KCNQ2, KCNQ3, and CACNA1A, are involved.
What is the difference between voltage-gated and ligand-gated channels?
Voltage-gated channels open in response to changes in membrane potential, whereas ligand-gated channels open in response to binding of a chemical ligand; GO:0022832 specifically requires voltage-dependent gating.
Why are voltage-gated sodium channels important in pain?
Voltage-gated sodium channels are central to nociceptive signaling, and their activators are studied for effects on pain pathways.
How do local anesthetics affect voltage-gated channels?
Local anesthetics block voltage-gated sodium channels, thereby reducing excitability.
What diseases are linked to voltage-gated channel activity?
Epilepsy, neurodevelopmental disorders, pain disorders, and cardiac arrhythmias have been linked to voltage-gated channel genes.
How can I study voltage-gated channel activity in the lab?
Patch-clamp electrophysiology, expression profiling, pharmacological assays, and CRISPR-based perturbation are common approaches.
Can CRISPR be used to model channelopathies?
Yes, CRISPR knockout, point mutation, and knock-in can model channel gene variants and test pharmacological rescue.
What is the role of KCNQ3 in neurodevelopmental disorders?
Mutations in KCNQ3 impair channel function, and lipophilic compounds can restore function to these mutant channels.
How does membrane voltage control channel opening?
The channel contains a voltage-sensing domain that responds to the transmembrane electric field, coupling voltage changes to pore opening.
Conclusion
GO:0022832 voltage-gated channel activity is a fundamental molecular function that converts membrane potential into ion flux, underpinning electrical signaling in nerves, muscle, and heart. Its clinical relevance is demonstrated by local anesthetics that block sodium channels, Kv7 openers for epilepsy, and pharmacological rescue of mutant KCNQ3 channels. Understanding the genes, mechanisms, and disease links of this term requires robust experimental models, and CRISPR-based knockout, point mutation, knock-in, and overexpression approaches provide the causal evidence needed to advance the field.
References
- 1. Perucca E et al.. 2025. Targeting Kv7 Potassium Channels for Epilepsy.. CNS Drugs 39(3):263-288 PMID: 39853501
- 2. Duncker DJ et al.. 2008. Regulation of coronary blood flow during exercise.. Physiol Rev 88(3):1009-86 PMID: 18626066
- 3. Deuis JR et al.. 2017. The pharmacology of voltage-gated sodium channel activators.. Neuropharmacology 127:87-108 PMID: 28416444
- 4. Lebedeva EA et al.. 2024. Voltage-gated ion channel's gene expression in the myocardium of embryo and adult chickens.. Dev Biol 516:130-137 PMID: 39127438
- 5. Yanagidate F et al.. 2007. Local anesthetics.. Handb Exp Pharmacol PMID: 17087121
- 6. Armstrong SA et al.. 2026. Physiology, Nociception.. PMID: 31855389
- 7. Edmond MA et al.. 2024. Lipophilic compounds restore function to neurodevelopmental-associated KCNQ3 mutations.. Commun Biol 7(1):1181 PMID: 39300259
- 8. Duclohier H. 2009. Structure-function studies on the voltage-gated sodium channel.. Biochim Biophys Acta 1788(11):2374-9 PMID: 19747894
